The tariff classification of Crisaborole (CAS No. 906673-24-3) in bulk powder form, from Spain
Issued August 2, 2017 by U.S. Customs and Border Protection.
Tariff classification
HTS codes: 2934.99.3000
Headings: 2934
Product description
Crisaborole is a nonsteroidal phosphodieterase-4 (PDE-4) inhibitor that is indicated for the treatment of mild to moderate atopic dermatitis.
CBP rationale
The applicable subheading for Crisaborole in bulk powder form will be 2934.99.3000, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds: Other: Other: Aromatic or modified aromatic: Other: Drugs.
Full text
N288331 August 2, 2017 CLA-2-29:OT:RR:NC:N2:238 CATEGORY: Classification TARIFF NO.: 2934.99.3000 Ms. Sheila Heerdt Ren Pharm International Ltd. 350 Jericho Turnpike, Suite 204 Jericho, NY 11753 RE: The tariff classification of Crisaborole (CAS No. 906673-24-3) in bulk powder form, from Spain Dear Ms. Heerdt: In your letter dated July 17, 2017, you requested a tariff classification ruling. Crisaborole is a nonsteroidal phosphodieterase-4 (PDE-4) inhibitor that is indicated for the treatment of mild to moderate atopic dermatitis. The applicable subheading for Crisaborole in bulk powder form will be 2934.99.3000, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds: Other: Other: Aromatic or modified aromatic: Other: Drugs.” The rate of duty will be 6.5 percent ad valorem. Currently, Crisaborole is not listed in the Pharmaceutical Appendix to the Tariff Schedule. Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided on World Wide Web at https://hts.usitc.gov/current. This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Judy Lee at [email protected]. Sincerely, Steven A. Mack Director National Commodity Specialist Division
More rulings on the same tariff codes
The tariff classification of Elinzanetant (CAS No. 929046-33-3) in bulk form and LYNKUET® (E linzanetant) Capsules in dosage form, from Germany
The tariff classification of Terazosin Hydrochloride Anhydrous (CAS No. 63074-08-8) in bulk form, from Germany
The tariff classification of Cabotegravir (CAS No. 1051375-10-0) in bulk powder form, from Brazil
The tariff classification of Ozanimod (CAS No. 1306760-87-1) in bulk form, from Taiwan
The tariff classification of Cabotegravir (CAS No. 1051375-10-0) in bulk powder form, from Brazil
The tariff classification of Aprepitant (CAS No. 170729-80-3) in bulk powder form, from Spain
The tariff classification of Brexpiprazole (CAS No. 913611-97-9) in bulk power form, from Taiwan
The tariff classification of Rivaroxaban (CAS No. 366789-02-8) in bulk powder form, from Mexico
The tariff classification of Prucalopride Succinate (CAS No. 179474-85-2) in bulk form, from India
The tariff classification of Ozanimod Hydrochloride (CAS No. 1618636-37-5), Brivaracetam (CAS No. 357336-20-0) and Tofacitinib Citrate (CAS No. 540737-29-9) in bulk form, from Taiwan
Searching CBP rulings the smart way
TariffLens semantically searches all 200,000+ CBP rulings, surfaces the ones that actually match your product, and builds defensible classifications backed by ruling citations.
Book a demo →